Cargando…

MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells

Triple-negative breast cancer (TNBC) is the most common type of cancer among females worldwide and is associated with poor prognosis. Poly ADP-ribose polymerase-1 (PARP1) inhibitors are effective against TNBC with mutations in the breast cancer type 1 susceptibility protein (BRCA1) and/or BRCA2 gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Xiaoqi, Jiang, Shanshan, Ruan, Simin, Guo, Zhaoze, Guo, Jingyun, Liu, Minfeng, Ye, Changsheng, Dong, Jianyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185508/ https://www.ncbi.nlm.nih.gov/pubmed/34080025 http://dx.doi.org/10.3892/mmr.2021.12187

Ejemplares similares

Cardiovascular risk factors and breast cancer incidence in a large middle-aged cohort study
por: Zeng, Xiaoqi, et al.
Publicado: (2022)

CircRNA_103809 Suppresses the Proliferation and Metastasis of Breast Cancer Cells by Sponging MicroRNA-532-3p (miR-532-3p)
por: Liu, Minfeng, et al.
Publicado: (2020)

Integrated analyses of long noncoding RNAs and mRNAs in the progression of breast cancer
por: Guo, Jingyun, et al.
Publicado: (2021)

Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Chen, Guanling, et al.
Publicado: (2017)

MiR-491-5p, as a Tumor Suppressor, Prevents Migration and Invasion of Breast Cancer by Targeting ZNF-703 to Regulate AKT/mTOR Pathway
por: Guo, Jingyun, et al.
Publicado: (2021)

Methylated biomarkers for breast cancer identified through public database analysis and plasma target capture sequencing
por: Luo, Can, et al.
Publicado: (2021)

Experimental Study of Magnetic Multi-Walled Carbon Nanotube-Doxorubicin Conjugate in a Lymph Node Metastatic Model of Breast Cancer
por: Ji, Jian, et al.
Publicado: (2016)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

Prevalence of breast fibroadenoma in healthy physical examination population in Guangdong province of China: a cross-sectional study
por: Zhu, Lijun, et al.
Publicado: (2022)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer
por: Zhu, Ying, et al.
Publicado: (2023)

Silencing of CHFR Sensitizes Gastric Carcinoma to PARP Inhibitor Treatment
por: Li, Yuan, et al.
Publicado: (2019)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
por: Cañedo, Eduardo Cepeda, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2022)

PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation
por: Marranci, Andrea, et al.
Publicado: (2023)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
por: Boerner, Julie L., et al.
Publicado: (2015)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer
por: Fu, Leilei, et al.
Publicado: (2016)

Silencing of PARP2 Blocks Autophagic Degradation
por: Jankó, Laura, et al.
Publicado: (2020)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
por: Gu, Yayun, et al.
Publicado: (2021)

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
por: Fröhlich, Lisa Marie, et al.
Publicado: (2023)

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells
por: Moustafa, Dina, et al.
Publicado: (2021)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
por: Kawanishi, Miki, et al.
Publicado: (2022)

ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer
por: Mei, Ying, et al.
Publicado: (2022)

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
por: Luo, Jiayan, et al.
Publicado: (2016)

Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A
por: vel Szic, Katarzyna Szarc, et al.
Publicado: (2017)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer
por: Song, Wei, et al.
Publicado: (2017)

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
por: Bustos, Matias A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_np10p8e9jgs39bja344lilj22i